-+ 0.00%
-+ 0.00%
-+ 0.00%

Affirm (AFRM) Stock Could Be 16% Overvalued Following Underwriting Model Launch

Simply Wall St·09/20/2026 03:33:24
Listen to the news

Affirm Holdings has rewarded long term holders with a very strong 3 year share price run, yet the recent pullback and fresh product news put a spotlight on a different issue. The open question now is whether the returns Affirm earns on its capital are strong enough to support where the stock trades today.

  • Over the past 3 years the share price has gained about 253%, which raises the stakes on whether the underlying capital returns can keep justifying that kind of re-rating.
  • The rollout of a transformer based underwriting model that approves more eligible borrowers and has produced better performing loans may support expectations for more efficient use of lending capital over time.
  • If you'd rather focus on earnings, this one's for you. See why Affirm Holdings's 12.5x P/E tells a different valuation story.

For investors, the debate is whether Affirm now earns sufficient returns on the capital it puts to work to make the current share price look sensible.

If you want to test the same question on other businesses that are being assessed on valuation grounds, take a look at 33 high quality undervalued stocks.

Does Affirm Holdings Look Pricey on Excess Returns?

The Excess Returns model evaluates how much profit Affirm Holdings can earn above its equity cost and what that implies for the stock at today’s price. It focuses on the future earning power of the existing and reinvested equity base, rather than just projecting cash flows year by year.

In this framework, Affirm is modeled with a Book Value of $16.26 per share and a Stable EPS of $3.49 per share, against a Cost of Equity of $1.84 per share. That results in an Excess Return of $1.65 per share and an average Return on Equity of 15.12%, building to a Stable Book Value of $23.08 per share. The projections indicate the business earns returns above its equity charge, yet the Excess Returns output still places the estimated intrinsic value meaningfully below the current share price of $71.21.

Affirm’s launch of a transformer based underwriting model, which management says has produced better performing loans and more completed purchases, helps explain why the market is willing to pay well above what the Excess Returns model currently supports. Find out what Affirm Holdings could be worth using our Excess Returns estimate.

The Affirm Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Affirm Holdings valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would make the stock worth materially more or less than it is today, and anchoring each storyline to a specific fair value that reflects the potential catalysts and the key risks so you can watch over time which version of Affirm Holdings' future is actually unfolding on the Community page.

One of the top community narratives on Affirm Holdings: 28% undervalued

"Expansion into new markets, product innovation, and strategic partnerships position Affirm for increased market share and revenue diversification..."

Discover why this Narrative puts Affirm Holdings at 28% undervalued.

One more Affirm Holdings check that belongs beside the price tag

Price and return metrics only tell part of the story for Affirm Holdings, since Simply Wall St's broader review has also flagged specific concerns that investors may want to weigh before getting comfortable. Take a closer look at 3 warning signs (2 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.